SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CCG-203971

Item No. 15075

CAS Registry No.:	1443437-74-8
Formal Name:	N-(4-chlorophenyl)-1-[3-(2-furanyl) benzoyl]-3-piperidinecarboxamide
MF:	$C_{23}H_{21}ClN_2O_3$
FW:	408.9
Purity:	≥90%
UV/Vis.:	λ_{max}: 252, 281 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CCG-203971 is supplied as a crystalline solid. A stock solution may be made by dissolving the CCG-203971 in the solvent of choice, which should be purged with an inert gas. CCG-203971 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of CCG-203971 in these solvents is approximately 50, 25, and 30 mg/ml, respectively.

Description

Signaling through small G proteins of the RhoA subfamily, including RhoC, induces actin-regulated cytosolic-to-nuclear translocation of the oncogene product megakaryoblastic leukemia 1 (MKL1), which binds to serum response factor (SRF).[1] The MKL1/SRF complex, in turn, activates the transcription of serum response element (SRE) regulated genes, stimulating cell migration, a process that is central to metastasis.[1] CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC_{50} = 6.4 µM), with 87% inhibition of SRE activation achieved at 100 µM.[2] This compound also inhibits PC-3 cell migration (IC_{50} = 4.2 µM), as determined by a scratch wound assay.[2] CCG-203971 causes no cytotoxicity when evaluated by WST-1 assay.[2] It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.[2]

References

1. Evelyn, C.R., Wade, S.M., Wang, Q., *et al.* CCG-1423: A small-molecule inhibitor of RhoA transcriptional signaling. *Mol. Cancer Ther.* **6(8)**, 2249-2260 (2007).
2. Bell, J.L., Haak, A.J., Wade, S.M., *et al.* Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. *Bioorg. Med. Chem. Lett.* **23(13)**, 3826-3832 (2013).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM